Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
25.14
-1.19 (-4.52%)
At close: Apr 28, 2026, 4:00 PM EDT
25.17
+0.03 (0.12%)
After-hours: Apr 28, 2026, 5:28 PM EDT
Tango Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Tango Therapeutics stock have an average target of 21.78, with a low estimate of 12 and a high estimate of 40. The average target predicts a decrease of -13.37% from the current stock price of 25.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tango Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 6 |
| Buy | 2 | 2 | 1 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 7 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $24 → $40 | Strong Buy | Maintains | $24 → $40 | +59.11% | Apr 27, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +19.33% | Apr 2, 2026 |
| Mizuho | Mizuho | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | -20.45% | Mar 11, 2026 |
| Stifel | Stifel | Strong Buy Maintains $15 → $24 | Strong Buy | Maintains | $15 → $24 | -4.53% | Mar 9, 2026 |
| Wedbush | Wedbush | Buy Maintains $15 → $19 | Buy | Maintains | $15 → $19 | -24.42% | Mar 6, 2026 |
Financial Forecast
Revenue This Year
n/a
from 62.38M
Revenue Next Year
n/a
EPS This Year
-1.36
from -0.87
EPS Next Year
-1.58
from -1.36
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.25 | -1.20 | ||||||
| Avg | -1.36 | -1.58 | ||||||
| Low | -1.57 | -2.12 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.